Cargando…
Drug interaction between tacrolimus and nilotinib in a patient with chronic myeloid leukemia after renal transplant
Nilotinib, a BCR‐ABL tyrosine kinase inhibitor, is a known inhibitor of CYP3A4 and could increase the concentration of drugs metabolized by CYP3A4. An immunosuppressive drug for nilotinib‐treated patients following transplant should be administered with careful pharmacokinetic monitoring because of...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412900/ https://www.ncbi.nlm.nih.gov/pubmed/28469859 http://dx.doi.org/10.1002/ccr3.900 |